Citius Oncology Statistics
Total Valuation
Citius Oncology has a market cap or net worth of $321.99 million. The enterprise value is $325.79 million.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, after market close.
Earnings Date | Aug 11, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Citius Oncology has 71.55 million shares outstanding. The number of shares has increased by 3.82% in one year.
Current Share Class | 71.55M |
Shares Outstanding | 71.55M |
Shares Change (YoY) | +3.82% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 0.17% |
Float | 5.50M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.11 |
P/TBV Ratio | 9.03 |
P/FCF Ratio | n/a |
P/OCF Ratio | 2,548.30 |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.36, with a Debt / Equity ratio of 0.11.
Current Ratio | 0.36 |
Quick Ratio | n/a |
Debt / Equity | 0.11 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -93.64% and return on invested capital (ROIC) is -53.05%.
Return on Equity (ROE) | -93.64% |
Return on Assets (ROA) | -22.41% |
Return on Invested Capital (ROIC) | -53.05% |
Return on Capital Employed (ROCE) | -60.35% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Citius Oncology has paid $816,480 in taxes.
Income Tax | 816,480 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.39% in the last 52 weeks. The beta is -0.06, so Citius Oncology's price volatility has been lower than the market average.
Beta (5Y) | -0.06 |
52-Week Price Change | -60.39% |
50-Day Moving Average | 1.21 |
200-Day Moving Average | 1.14 |
Relative Strength Index (RSI) | 94.43 |
Average Volume (20 Days) | 3,061,826 |
Short Selling Information
The latest short interest is 113,580, so 0.16% of the outstanding shares have been sold short.
Short Interest | 113,580 |
Short Previous Month | 25,500 |
Short % of Shares Out | 0.16% |
Short % of Float | 2.06% |
Short Ratio (days to cover) | 0.52 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -25.16M |
Pretax Income | n/a |
Net Income | -25.98M |
EBITDA | n/a |
EBIT | -25.16M |
Earnings Per Share (EPS) | -$0.37 |
Full Income Statement Balance Sheet
The company has $112 in cash and $3.80 million in debt, giving a net cash position of -$3.80 million or -$0.05 per share.
Cash & Cash Equivalents | 112 |
Total Debt | 3.80M |
Net Cash | -3.80M |
Net Cash Per Share | -$0.05 |
Equity (Book Value) | 35.64M |
Book Value Per Share | 0.50 |
Working Capital | -31.70M |
Full Balance Sheet Cash Flow
Operating Cash Flow | 126,353 |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Citius Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.82% |
Shareholder Yield | -3.82% |
Earnings Yield | -8.07% |
FCF Yield | n/a |
Analyst Forecast
The average price target for Citius Oncology is $6.00, which is 33.33% higher than the current price. The consensus rating is "Buy".
Price Target | $6.00 |
Price Target Difference | 33.33% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |